Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

More time needed for US ICD (implantable cardioverter defibrillator) implantee registry:

This article was originally published in Clinica

Executive Summary

The US Heart Rhythm Society and the American College of Cardiology have asked Medicare officials to grant a period of grace before they require that all beneficiaries receiving an implantable cardioverter defibrillator be enrolled in a national registry. The medical groups said there is simply not enough time to establish the registry by the January 1 deadline set by the Centers for Medicare & Medicaid Services (CMS). A variety of details must be worked out first, including finding a source of funding and setting up a registry infrastructure, the groups said. The HRS is leading a working group that CMS has asked to address such issues. The group should advise CMS on a reasonable time for setting up the registry, the letter said.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT060142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel